|
|
||||||||
Institute of Microbiology and Immunology, Section of Pathobiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Palackého 1-3, 612 42 Brno, Czech Republic
Correspondence Alois Cizek cizeka{at}vfu.cz
Received July 30, 2003
Accepted January 15, 2004
The agar dilution method was used to investigate the sensitivity to pleuromutilins of 100 isolates of Brachyspira hyodysenteriae isolated from 63 pig farms between 1997 and 2001. In the period under investigation, MICs to both tiamulin and valnemulin increased, with differences between the periods 199798 and 19992001 being statistically significant (P < 0.001 for tiamulin and P < 0.0001 for valnemulin). Between 1997 and 2001, the MIC50 and MIC90 of tiamulin increased from 0.062 and 0.25 µg ml-1, respectively, to 1.0 and 4.0 µg ml-1. Valnemulin MIC50 and MIC90 were
0.031 µg ml-1 in 1997 and by 2001 were respectively, 2.0 and 8.0 µg ml-1. The increase in MICs of tiamulin and valnemulin demonstrated in this study reflect the intensity of pleuromutilin use in the treatment of swine dysentery in the Czech Republic.
Abbreviations: SD, swine dysentery; TSBA, trypticase soy agar with 5 % ovine blood; WCABA, WilkinsChalgren anaerobe agar with 5 % ovine blood.
| INTRODUCTION |
|---|
|
|
|---|
|
In the past, dilution methods with various blood agars were used in studies of B. hyodysenteriae sensitivity to antimicrobials (Kitai et al., 1987; Molnar, 1996; Hommez et al., 1998; Fossi et al., 1999), and attempts were also made to verify the broth dilution procedure (Weber & Earley, 1991; Buller & Hampson, 1994). In recent years, attention has focused on the standardization of these methods and a better understanding of the mechanism that triggers B. hyodysenteriae antimicrobial resistance, including its genetic background (Karlsson et al., 1999, 2001, 2003).
The aim of this study was to evaluate tiamulin and valnemulin MICs using a set of randomly selected isolates of B. hyodysenteriae obtained from farms in the Czech Republic between 1997 and 2001, and to assess any changes in sensitivity to pleuromutilins.
| METHODS |
|---|
|
|
|---|
Antimicrobial agents.
Tiamulin and valnemulin powders (Novartis) were dissolved and diluted in accordance with the instructions of the drug manufacturer and of the National Committee for Clinical Laboratory Standards (NCCLS, 2001). Stock solutions were stored in polystyrene vials at -20 °C for 5 months. When needed, they were thawed and used the same day.
Agar dilution method.
WilkinsChalgren anaerobe agar (CM 619, Oxoid) with 5 % ovine blood (WCABA) was used to determine MICs. After thawing the antibacterial substance to be tested, a series of twofold dilutions was prepared and 2 ml of the dilutions were pipetted into sterile Petri dishes 90 mm in diameter, where they were mixed with 18 ml WCABA. In this way, the following concentrations of active substances were obtained: 0.031, 0.062, 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16 µg ml-1. The dishes were pre-dried and used the same day. Frozen isolates of B. hyodysenteriae were inoculated on TSBA and incubated in an anaerobic jar using a gas generating kit (BR38, Oxoid) for 34 days at 37 °C. Purity of the cultures was checked microscopically using culture smears stained with 1 % crystal violet solution. Pure B. hyodysenteriae cultures were scraped from TSBA using sterile cotton swabs and suspended in 2 ml sterile PBS. The turbidity was adjusted with a photometer (Densi-La-Meter, LIAP, Latvia) to 1 McFarland standard. Twenty microlitres of the working suspension, which was prepared by a hundredfold dilution, was applied to the agar surface, which brought the final inoculum on the agar surface to approximately 104 c.f.u. per spot. The isolates of B. hyodysenteriae to be tested were pipetted onto the surface of pre-dried WCABA with twofold dilutions of the individual antimicrobial agent. Each dish was inoculated with six isolates in spots distributed evenly over the surface in a rosette-like pattern. After 34 days incubation at 37 °C, the result was read as the MIC, i.e. the lowest concentration of the drug tested that prevented growth and haemolysis of the isolate on the inoculated spot.
The growth of B. hyodysenteriae isolates was evaluated in parallel with controls on WCABA with no antimicrobial agents added. Three independent examinations of each of the B. hyodysenteriae isolates were made. To check the quality of the agar dilution tests, the strains B. hyodysenteriae B78T (ATCC 27164T), Staphylococcus aureus ATCC 29213 and Streptococcus pneumoniae ATCC 49619 (Odland et al., 2000; NCCLS, 2001) were used. Each batch of WCABA plates was tested with the control strains listed above.
Evaluation of results.
MICs obtained were documented and statistically evaluated by chi-square tests using MS Excel with the Analyse-it module. When a difference of one dilution was found in a set of three repeated tests, the value that was obtained twice was used for further computations. In the case of a two-dilution difference, the mean value was used. Results with differences greater than two dilutions were not evaluated, and MIC tests were repeated. A total of seven isolates (four for tiamulin and three for valnemulin) were retested. The new results were evaluated in the same way. The values obtained for each of the drugs tested were used for the computation of MIC50, MIC90 and the range of MICs.
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
The distribution of MICs for tiamulin and valnemulin for the B. hyodysenteriae isolates over the period investigated is given in Table 1. Between 1997 and 1998, MICs of the two pleuromutilins remained practically unchanged. Tiamulin MICs were around 0.062 and 0.125 µg ml-1, and valnemulin MICs for an absolute majority of isolates were
0.031 µg ml-1. Even in those years, however, a few B. hyodysenteriae isolates with MICs of 1 and 2 µg ml-1 were found (Fig. 2, Table 1). The upward trend in MICs observed between 1999 and 2001 was reflected in gradually decreasing B. hyodysenteriae isolate susceptibility. In 1999, 50 % of the isolates tested still had an MIC of < 0.125 µg valnemulin ml-1. In the 20002001 period, almost no MICs below 0.125 µg ml-1 were found for either of the pleuromutilins (Fig. 2, Table 1). MICs of tiamulin and valnemulin were significantly different in the period 199798 compared with 19992001 (P < 0.001 for tiamulin and P < 0.0001 for valnemulin). Similar decreases in the susceptibility of B. hyodysenteriae isolates to tiamulin were also reported in Poland, Hungary, Finland and Germany (Binek et al., 1994; Molnár, 1996; Fossi et al., 1999; Karlsson et al., 2002b).
|
|
A comparison between tiamulin and valnemulin MICs proved interesting. In 1997 and 1998, before valnemulin was registered for the therapy of SD in the Czech Republic, MICs of the two drugs differed by only one or two dilutions. This difference is not considered significant (Odland et al., 2000; NCCLS, 2001). B. hyodysenteriae isolates whose tiamulin MICs averaged 0.125 µg ml-1 had valnemulin MICs
0.031 µg ml-1. This relationship was also demonstrable in B. hyodysenteriae isolates from the years 1999 to 2001. In addition, B. hyodysenteriae isolates with tiamulin MICs
0.5 µg ml-1 showed increased valnemulin MICs (Fig. 2). In 1997, before valnemulin was registered, a B. hyodysenteriae isolate with an increased valnemulin MIC was found on a farm. Such findings suggest the existence of cross resistance between the two pleuromutilins.
A summary of MIC50, MIC90 and MIC ranges is presented in Table 2. The gradual increase of tiamulin MIC50 values in the first 3 years (from 0.062 to 0.125 µg ml-1), accelerated in 2000 and 2001 (from 0.5 to 1.0 µg ml-1). Tiamulin MIC90 values also increased gradually from 0.25 µg ml-1 in 1997 and 1998 to 1.0 µg ml-1 in 1999, and showed a twofold annual increase in the period which followed. Valnemulin MIC90 values followed the same pattern of gradual increases. In 2001, there were no tiamulin MICs below 0.125 µg ml-1 or valnemulin MICs below 0.062 µg ml-1. In most cases when tiamulin MICs for B. hyodysenteriae isolates were between 1.0 and 4.0 µg ml-1, the effectiveness of the drug was reduced or absent in pig herds when medicated feeds were used for therapy. The failure of the drugs may have, however, been caused by a number of factors related either to the host, technology or the environment. The proposed clinical breakpoint of tiamulin resistance (Rønne & Szancer, 1990), particularly with regard to peroral administration, seems to be in need of some adjustment. Karlsson et al. (2003) suggested that a lower microbiological breakpoint for resistance evaluation should be used. It is important that there be increased awareness of these problematic isolates of B. hyodysenteriae.
|
This study records the development of decreased sensitivity of B. hyodysenteriae isolates to pleuromutilins in the Czech Republic. However, the study may have been influenced by the choice of B. hyodysenteriae isolates, because B. hyodysenteriae isolates from the last 2 years were mainly from farms experiencing problems with a lack of clinical efficiency of pleuromutilins, and by the testing methods used. On the other hand, MICs obtained in tests with control strains (Table 3) corresponded to the acceptable quality-control range (NCCLS, 2002; Karlsson et al., 2003). A comparison between the agar dilution procedure used here and the broth dilution procedure (Karlsson et al., 2002a) has demonstrated certain differences between the two, in that some B. hyodysenteriae isolates showed lower MICs for tiamulin, tylosin and lincomycin when tested by the broth dilution procedure. This fact should be borne in mind in a critical assessment of the higher MICs reported in the present study. In a more general sense, however, results obtained by the two methods have shown good agreement (Karlsson et al., 2002a). This, however, does not change the fact that a significant increase in MIC for both pleuromutilins was demonstrated amongst Czech B. hyodysenteriae isolates during the reported period.
|
Initially, the occurrence of B. hyodysenteriae isolates with reduced sensitivity to pleuromutilins was limited to pig farms with enzootic SD, where antimicrobial agents were not rotated systematically, and, at the same time, inadequate doses of the drug were administered due to poor mixing of the active substance with the feed. In the last 2 years of the study period, B. hyodysenteriae isolates with reduced sensitivity were being spread by unregulated shipments of pigs.
The increasing number of B. hyodysenteriae isolates with decreased susceptibility demonstrated in this present study should alert veterinary surgeons and pig farmers to the need for a very responsible approach to the selection and use of antimicrobial agents. Only a prudent policy of antibiotic use can help to maintain the effectiveness of pleuromutilins in the treatment of SD by strategic medication in pig production.
| ACKNOWLEDGEMENTS |
|---|
|
|
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. Jonasson, M. Andersson, T. Rasback, A. Johannisson, and M. Jensen-Waern Immunological alterations during the clinical and recovery phases of experimental swine dysentery. J. Med. Microbiol., July 1, 2006; 55(Pt 7): 845 - 855. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Long, L. H. Hansen, L. Jakobsen, and B. Vester Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1458 - 1462. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |